• 1
    Ito K, Schröder FH. Informed consent for PSA-based screening: European view. Urology 2003; 61: 202.
  • 2
    Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 128390.
  • 3
    Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program: The Prostate Cancer Education Council. Urology 1996; 47: 8639.
  • 4
    Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 733.
  • 5
    ParkinDM, WhelanSL, FerlayJ, RaymondL, YoungJ, eds. Cancer incidence in five continents, Vol VII. Lyon: IARC Science Pub, No. 143, 1997.
  • 6
    Shibata A, Whittemore AS, Imai K, Kolonel LN, Wu AH, John EM, Stamey TA, Paffenbarger RS. Serum levels of prostate-specific antigen among Japanese-American and native Japanese men. J Natl Cancer Inst 1997; 89: 171620.
  • 7
    Crawford D, Chia D, Andriole GL, Reding D, Gelmann EP, Gohagan JK, Pinsky P, Hayes RB, Levin DL, Fagerstrom RM, Kramer B. PSA testing interval, reduction in screening intervals: data from the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. J Urol 2002; 167: 99100.
  • 8
    Ito K, Yamamoto T, Ohi M, Takechi H, Kurokawa K, Suzuki K, Yamanaka H. Natural history of PSA increase with and without prostate cancer. Urology 2003; 62: 649.
  • 9
    Catalona WJ, Ramos CG, Carvalhal GF, Yan Y. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology 2000; 55: 7915.
  • 10
    Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HA Jr. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. J Urol 2001; 165: 75760.
  • 11
    Catalona WJ, Partin AW, Finlay JA, Chan DW, Rittenhouse HG, Wolfert RL, Woodrum DL. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology 1999; 54: 2204.
  • 12
    Carter HB, Epstein JI, Partin AW. Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. Urology 1999; 53: 12630.
  • 13
    Woolf SH. Screening for prostate cancer with prostate-specific antigen: an examination of the evidence. N Engl J Med 1995; 333: 14015.
  • 14
    Ito K, Yamamoto T, Kubota Y, Suzuki K, Fukabori Y, Kurokawa K, Yamanaka H. Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer. Urology 2000; 56: 27882.
  • 15
    Ito K, Yamamoto T, Ohi M, Takechi H, Kurokawa K, Suzuki K, Yamanaka H. Possibility of re-screening intervals for more than one year in men with PSA levels of 4.0 ng/ml or less. Prostate 2003; 57: 813.
  • 16
    Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, et al. Prostate, lung, colorectal and ovarian cancer screening trial project team.: design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000; 21: 273S309S.
  • 17
    Schröder FH, Kranse R, Rietbergen J, Hoedemaeke R, Kirkels W. The European Randomized Study of Screening for Prostate Cancer (ERSPC): an update. Members of the ERSPC, Section Rotterdam. Eur Urol 1999; 35: 53943.
  • 18
    Standaert B, Denis L. The European Randomized Study of Screening for Prostate Cancer: an update. Cancer 1997; 80: 18304.
  • 19
    Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Huntington). 2000; 14: 26772, 277–8, 280.
  • 20
    Ito K, Kubota Y, Yamamoto T, Suzuki K, Fukabori Y, Kurokawa K, Yamanaka H. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less. Cancer 2001; 91: 4451.